B-cell-targeted therapy in adult glomerulonephritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 12, 2013, Pages 1691-1706

  Tanna, Anisha ^a   Tam, Frederick W K ^a   Pusey, Charles D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti CD20; B lymphocyte; Glomerulonephritis; Renal

Indexed keywords

ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CD22 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPRATUZUMAB; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; STEROID; VELTUZUMAB;

ALLERGIC REACTION; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; B LYMPHOCYTE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM CANCER; CRYOGLOBULINEMIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG TARGETING; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC MEMBRANOUS NEPHRITIS; INFECTION; INFUSION RELATED REACTION; LIPOID NEPHROSIS; LUNG INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASTIC DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE DISEASE; NEPHROTIC SYNDROME; PATHOGENESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; GLOMERULONEPHRITIS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84887933112     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.851191     Document Type: Review

References (106)

1. Luetscher JA Jr, Deming QB. Treatment of nephrosis with cortisone. J Clin Invest 1950;29:1576-87
2. Chasis H, Goldring W, Baldwin DS. Effect of febrile plasma, typhoid vaccine and nitrogen mustard on renal manifestations of human glomerulonephritis. Proc Soc Exp Biol Med 1949;71:565-7
3. Mauri C. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010;22:761-7
4. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-19
5. Nagai M, Hirayama K, Ebihara I, et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: Association with disease activity. Nephron Clin Pract 2011;118:c339-45
6. Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: A clinically relevant cellular process. Ann Rheum Dis 2011;70:2229-33
7. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-17
8. Tedder TF, Streuli M, Schlossman SF, et al. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988;85:208-12
9. Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
10. Salama AD, Pusey CD. Drug insight: Rituximab in renal disease and transplantation. Nat Clin Pract Nephrol 2006;2:221-30
11. Ramanath V, Nistala R, Chaudhary K. Update on the role of rituximab in kidney diseases and transplant. Expert Opin Biol Ther 2012;12:223-33
12. Scott SD. Rituximab: A new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6:195-7
13. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine 2008;87:345-64
14. FDA. Available from: Http://www.fda. gov/Drugs/DrugSafety/ PostmarketDrugSafety InformationforPatientsandProviders/ ucm109106.htm
15. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
16. Dorner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag 2007;3:953-9
17. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-41
18. Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013;52:1313-22
19. Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64
20. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90
21. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010;22:732-9
22. Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol 2010;29:1031-5
23. Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005;25:298-302
24. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
25. Mosak J, Furie R. Breaking the ice in systemic lupus erythematosus: Belimumab, a promising new therapy. Lupus 2013;22:361-71
26. Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 2013;40:579-89
27. Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010;13:3-11
28. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80
29. Medawar W, Green A, Campbell E, et al. Clinical and histopathologic findings in adults with the nephrotic syndrome. Irish J Med Sci 1990;159:137-40
30. Cohen CD, Calvaresi N, Armelloni S, et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 2005;18:328-33
31. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
32. Cattran DC, Kim J. Is long-term prediction in membranous nephropathy (MGN) better than the weatherman's forecast capacity? Clin J Am Soc Nephrol 2012;7:1203-5
33. Cattran D. Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 2005;16:1188-94
34. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50
35. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 2003;14:1851-7
36. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-25
37. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010;5:2188-98
38. Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7
39. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1416-25
40. Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013;12:854-9
41. Murtas C, Bruschi M, Candiano G, et al. Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. Clin J Am Soc Nephrol 2012;7:1394-400
42. Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol 2013;24:702-11
43. Shalhoub RJ. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974;2:556-60
44. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003;23:147-60
45. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011;385-346
46. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: Implications for patients' management. Nat Rev Nephrol 2013;9:154-69
47. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006;354:1961-3
48. Nozu K, Iijima K, Fujisawa M, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005;20:1660-3
49. Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012;23:1117-24
50. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin J Am Soc Nephrol 2011;6:1308-15
51. Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013; Epub ahead of print
52. Fernandez-Fresnedo G, Segarra A, Gonzalez E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4:1317-23
53. Araya CE, Dharnidharka VR. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: A systematic review. J Transplant 2011;2011:374213
54. Kumar J, Shatat IF, Skversky AL, et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol 2013;28:333-8
55. Tsagalis G, Psimenou E, Nakopoulou L, et al. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 2011;35:420-5
56. Korbet SM, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 1988;8:291-7
57. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: Clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2:445-53
58. Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013;83:511-16
59. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient. Kidney Int 2012;82:840-56
60. Kawasaki Y. The pathogenesis and treatment of pediatric Henoch-Schonlein purpura nephritis. Clin Exp Nephrol 2011;15:648-57
61. Aktas B, Topcuoglu P, Kurt OK, et al. Severe Henoch-Schonlein purpura induced by cytarabine. Ann Pharmacother 2009;43:792-3
62. Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: Case report. Nephrol Dial Transplant 2011;26:2044-6
63. El-Husseini A, Ahmed A, Sabucedo A, et al. Refractory henoch-schonlein purpura: Atypical aetiology and management. J Renal Care 2013;39:77-81
64. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92
65. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;2:265-70
66. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 2003;41:776-84
67. Falk RJ, Jennette JC. ANCA are pathogenic -oh yes they are! J Am Soc Nephrol 2002;13:1977-9
68. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63
69. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43
70. Rutgers A, Kallenberg CG. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 2012;24:245-51
71. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40
72. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005;257:540-8
73. Omdal R, Wildhagen K, Hansen T, et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005;34:229-32
74. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
75. Mansfield N, Hamour S, Habib AM, et al. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011;26:3280-6
76. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
77. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
78. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2012;51:634-43
79. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): A single-center ten-year experience. Arthritis Rheum 2012;64:3770-8
80. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9
81. Wilde B, Thewissen M, Damoiseaux J, et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1416-19
82. Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5 (+) B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013;8:382-91
83. Monach PA, Warner RL, Tomasson G, et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis 2013;72:1342-50
84. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 2012;8:505-14
85. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26
86. Lightstone L. Lupus nephritis: Where are we now? Curr Opin Rheumatol 2010;22:252-6
87. Condon MB, Ashby D, Pepper R, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6
88. Jonsdottir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology 2013;52:847-55
89. Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012;71:875-7
90. Mysler E, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, Phase III study. Arthritis Rheum 2013;65:2368-79
91. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
92. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8
93. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Lupus 2013;22:63-72
94. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88
95. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308
96. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine 2002;81:398-409
97. Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: New insights based on 64 cases. Medicine 2013;92:61-8
98. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasuclitis. Arthritis Rheum 2012;64:843-53
99. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989;320:8-13
100. Michel PA, Dahan K, Ancel PY, et al. Rituximab treatment for membranous nephropathy: A French clinical and serological retrospective study of 28 patients. Nephron Extra 2011;1:251-61
101. Cravedi P, Sghirlanzoni MC, Marasa M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 2011;33:461-8
102. Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009;4:1083-8
103. Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 2009;4:734-44
104. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre. Rheumatology 2013; [Epub ahead of print]
105. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-400
106. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68